Results demonstrate that DIAG723, the Company's lead clustering antibody, can prevent PAH, offering the potential as a first-in-class PAH treatment WATERTOWN, Mass., Sept. 29, 2025 /PRNewswire/ -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling...
Hence then, the article about diagonal therapeutics to present new preclinical data demonstrating disease modifying potential of diag723 in pulmonary arterial hypertension at 2025 ers congress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of DIAG723 in Pulmonary Arterial Hypertension at 2025 ERS Congress )
Also on site :
- Sean Hogan’s ‘The Dark Gets In’ Boarded for Worldwide Sales by Blue Finch Films Ahead of Beyond Fest Bow (EXCLUSIVE)
- R.E.M. Reissues Its Second Album 42 Years Later — And the Limited-Quantity Pressing Could Sell Out Fast
- Inter Miami vs San Diego: When and Where to Watch Messi in MLS 2026